Osmotica Pharmaceuticals PLC (OSMT) Given Consensus Recommendation of “Buy” by Brokerages

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has earned an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has given a strong buy recommendation to the company.

Brokerages have set a twelve-month consensus price target of $19.00 for the company, according to Zacks. Zacks has also assigned Osmotica Pharmaceuticals an industry rank of 93 out of 257 based on the ratings given to its competitors.

OSMT has been the topic of several research analyst reports. Wells Fargo & Co initiated coverage on Osmotica Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $18.00 price objective on the stock. Royal Bank of Canada initiated coverage on Osmotica Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on Osmotica Pharmaceuticals in a research report on Monday. They issued a “buy” rating on the stock.

Shares of Osmotica Pharmaceuticals stock traded down $0.86 during trading hours on Tuesday, hitting $7.66. The company’s stock had a trading volume of 59,606 shares, compared to its average volume of 67,750. Osmotica Pharmaceuticals has a 12-month low of $7.03 and a 12-month high of $9.90.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.

Featured Article: Fundamental Analysis

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply